Navigation Links
PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
Date:2/1/2012

ates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which "Ri
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
4. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
5. PAREXEL Ranks as a "Best 5 Outsourcing Company for the Pharmaceutical Industry" by IAOP®
6. PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM)
7. PAREXEL International to Present at Wells Fargo Healthcare Conference
8. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
9. PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
11. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... OHAUS Corporation, a leading worldwide manufacturer ... scales, proudly announces its Explorer line of analytical ... 2014 “Readers' Choice” Award for best balance. ... was voted the best laboratory balance by the ... “excellence in product design and performance for the ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 ... una filiale di BGI, la maggiore organizzazione di genomica ... nuovo servizio di sequenziamento dell,intero esoma umano con base ... Complete Genomics, molto apprezzata nel settore per ... con il 99.999% di precisione e una rilevazione altamente ...
(Date:7/22/2014)... PITTSBURGH , July 22, 2014 ... maker of MD-Cu 29 antimicrobial copper announces Pullman ... to the first EPA-registered antimicrobial solid touch surface, at ... than 99.9% of MRSA, E-coli and other bacteria within 2 ... hospital in protecting against bacteria and infectious diseases in ...
(Date:7/22/2014)... , July 22, 2014  The Broad Institute ... from philanthropist Ted Stanley aimed at ... new treatments based on molecular understanding to hundreds ... The Stanley commitment – the largest ... for scientific research in general – will support ...
Breaking Biology Technology:OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10
... May 24, 2012  Novocure™, a commercial stage private oncology ... centers of excellence will join the seven existing clinical ... to patients with recurrent GBM. These fifteen clinical centers ... GBM is both the deadliest and ...
... NEW YORK, May 23, 2012 Exosome Diagnostics, ... for use in personalized and non-invasive cancer diagnostics, ... utility of non-invasive sampling of patients, urine to ... In the first study, the presence of a ...
... imaging system that scans 3D models of historical buildings using ... a human pilot onboard. This is the first 3D imaging ... technologies, and virtual representation of models to produce a realistic ... this project is to obtain a 3D model of a ...
Cached Biology Technology:Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 2Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 3Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 4Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer 2Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer 3A new imaging system produces 3-D models of monuments using unmanned aircraft 2
(Date:7/21/2014)... researchers have detected genetic fragments of Middle East Respiratory ... holding a camel infected with the virus. The work, ... open-access journal of the American Society for Microbiology, indicates ... disease can be transmitted through the air. , MERS, ... has been identified in 699 people as of June ...
(Date:7/21/2014)... ROUGE LSU,s Mark Batzer, Boyd Professor and Dr. ... Sciences in the College of Science, contributed to an ... titled "The Common Marmoset Genome Provides Insight into Primate ... Batzer contributed analysis of "jumping genes," or mobile elements ... mechanism in the genome. The marmoset is important because ...
(Date:7/21/2014)... every movement, researchers have shown for the first time ... farms and pipelines. Those man-made structures probably serve as ... study published in the Cell Press journal Current ... shocked when I first saw the stunning grid pattern ... wind farm in the United Kingdom, says Deborah Russell ...
Breaking Biology News(10 mins):Middle East Respiratory Syndrome coronavirus detected in the air of a Saudi Arabian camel barn 2LSU's Mark Batzer contributes to Nature Genetics article on marmoset genome 2Seals forage at offshore wind farms 2
... is a newly published careers book written specifically ... contains essential information about the job market, how ... advice on improving CV writing and interview technique. ... biologists who have forged successful careers within and ...
... director-general of the World Health Organization warned of "an ... the not-too-distant future, said Margaret Chan, "Things as common ... once again kill." , The culprit: the growing ability ... phenomenon known as antibiotic resistance. Chan singled out several ...
... on earth, yet their unique relationship with fire makes them ... of these giants, published in New Phytologist , seeks ... a debate which may determine their future. Gigantic trees ... 100,000 global tree species only 50, less than 0.005%, reach ...
Cached Biology News:WSU researcher to study ecology of antibiotic resistance 2Do Australia's giant fire-dependent trees belong in the rainforest? 2
... demand is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... work and endeavour! Bring us your idea and ... internationally. We work under ISO 9001 quality assurance ...
... EKMax™ is a recombinant preparation of ... EKMax™ Enterokinase is expressed and isolated from ... highly purified enzyme preparation (2). It recognizes ... bond after the lysine residue. The enzyme ...
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
...
Biology Products: